Comparison of methods to test antibiotic combinations against heterogeneous populations of multiresistant Pseudomonas aeruginosa from patients with acute infective exacerbations in cystic fibrosis.
Multiresistant Pseudomonas aeruginosa isolates can chronically infect patients with cystic fibrosis. Acute infective exacerbations are treated with combinations of two antipseudomonal antibiotics. Patients may respond clinically even if the bacteria are resistant, possibly due to antimicrobial synergy. The challenge for testing for synergy in vitro is that there is no standardized method, and the antibiotic susceptibility in a population of P. aeruginosa isolates in a single sputum sample can vary. We therefore compared (i) antibiotic combinations with different examples of resistant bacteria from the same sputum sample and (ii) the results of synergy testing by different methods. Antibiotic synergy was tested by using resistant P. aeruginosa isolates recovered from sputum samples taken just before the start of treatment for an acute infective exacerbation. Several examples of each morphotype of P. aeruginosa were tested by cidal checkerboard, time-kill curve, and multiple-combination bactericidal testing. The isolates were typed by pulsed-field gel electrophoresis (PFGE). The results were compared with the clinical and microbiological responses to 14 days of antibiotic treatment. Forty-four resistant isolates from nine patients were tested. Some P. aeruginosa isolates with the same morphotype and PFGE pulsotype had different results by synergy testing. There was a poor correlation between the results of the different methods of synergy testing, and no one method would have predicted the response to treatment in all patients. The in vitro effects of antibiotic combinations against different isolates from the same sputum sample can vary, and the results depend on the methodology used. The role of combination testing for the treatment of antibiotic-resistant P. aeruginosa in acute exacerbations of chronic infection in patients with cystic fibrosis needs to be reviewed.
Foweraker
Juliet E
JE
Department of Microbiology, Papworth Hospital, Papworth Everard, Cambridge CB3 8RE, United Kingdom. juliet.foweraker@papworth.nhs.uk
Laughton
Christian R
CR
Brown
Derek F
DF
Bilton
Diana
D
D000208:Acute Disease; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D003550:Cystic Fibrosis / Q000382:microbiology*; D024901:Drug Resistance, Multiple, Bacterial; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D016521:Electrophoresis, Gel, Pulsed-Field; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000379:methods*; D011552:Pseudomonas Infections / Q000150:complications / Q000188:drug therapy*; D011550:Pseudomonas aeruginosa / Q000187:drug effects*; D013183:Sputum / Q000382:microbiology
D000900:Anti-Bacterial Agents
Am J Respir Crit Care Med. 2000 Dec;162(6):2241-5
11112146
Methods Mol Med. 1998;15:33-50
21390741
Antimicrob Agents Chemother. 1992 Jan;36(1):71-6
1590704
Respiration. 2006;73(1):27-33
16113513
Paediatr Respir Rev. 2007 Sep;8(3):249-55
17868923
Eur Respir J. 2004 Oct;24(4):631-7
15459143
Thorax. 2003 Sep;58(9):794-6
12947141
J Antimicrob Chemother. 2005 Jun;55(6):921-7
15883175
J Med Microbiol. 2004 Sep;53(Pt 9):903-910
15314198
Clin Infect Dis. 2002 Mar 1;34(5):634-40
11823954
Lancet. 2005 Aug 6-12;366(9484):463-71
16084254
Am J Respir Crit Care Med. 2008 May 1;177(9):995-1001
18263800
Chest. 2003 May;123(5):1495-502
12740266
J Antimicrob Chemother. 2005 Aug;56(2):353-9
15967767
Clin Infect Dis. 1996 Sep;23(3):532-7
8879776
J Antimicrob Chemother. 2002 Nov;50(5):657-64
12407121
N Engl J Med. 1994 Sep 8;331(10):637-42
7503821
J Antimicrob Chemother. 1990 Aug;26(2):247-59
2170321
BMC Microbiol. 2007 May 23;7:45
17521417
J Infect Dis. 1983 Mar;147(3):559-67
6339649
J Clin Microbiol. 2006 Jul;44(7):2601-4
16825392
Antimicrob Agents Chemother. 1998 Apr;42(4):953-5
9559819
Rev Infect Dis. 1983 Nov-Dec;5 Suppl 5:S874-9
6419313
Antimicrob Agents Chemother. 2003 Mar;47(3):905-9
12604520
J Antimicrob Chemother. 2001 Jul;48 Suppl 1:5-16
11420333
Antimicrob Agents Chemother. 1987 Jan;31(1):108-10
3105439
Mol Microbiol. 2003 Dec;50(5):1477-91
14651632
J Clin Microbiol. 2004 Nov;42(11):5229-37
15528719
Antimicrob Agents Chemother. 1996 Mar;40(3):677-83
8851592
J Antimicrob Chemother. 1987 Mar;19(3):321-9
3106305
Eur Respir J. 2000 Oct;16(4):749-67
11106223
Antimicrob Agents Chemother. 1990 Mar;34(3):487-8
2110438
Antimicrob Agents Chemother. 1981 May;19(5):777-85
6794444
Eur J Clin Microbiol Infect Dis. 2006 Jan;25(1):25-30
16402226
Antimicrob Agents Chemother. 1995 Nov;39(11):2411-4
8585718
J Clin Microbiol. 1999 Jun;37(6):1771-6
10325322
Aust N Z J Med. 1999 Feb;29(1):15-21
10200808
J Clin Microbiol. 2004 May;42(5):1915-22
15131149
J Antimicrob Chemother. 1994 Sep;34(3):331-41
7829408